May 16, 2011

Sanofi and Glenmark Pharmaceuticals Sign License Agreement on Novel Monoclonal Antibody for Crohn’s Disease and Other Chronic Autoimmune Disorders

 

Sanofi and Glenmark Pharmaceuticals Sign License Agreement on Novel Monoclonal Antibody for Crohn’s Disease and Other Chronic Autoimmune Disorders

Paris, France – May 16, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it has entered into a license agreement with Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), for the development and commercialization of GBR500, a novel monoclonal antibody to treat Crohn’s Disease and other chronic autoimmune disorders. The closing of the transaction is subject to customary conditions, including the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.